Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. The US regulator has cleared ...
Why does mrbeast change his thumbnails? That's a good question. it'll have a different thumbnail. like world's fastest man ...
The Aviationist on MSN
Lockheed Martin Test Fires FIM-92 Stinger’s Possible Successor
Lockheed Martin completed the first flight test of its Next-Generation Short-Range Interceptor (NGSRI) design as part of the competition for the FIM-92 ...
January 15, 2026 • Part memoir and part fiction, Barnes' hybrid novel publishes the day after his 80th birthday. He's been living with a rare form of blood cancer for six years.
State regulators have denied a Baltimore Gas and Electric Co. request to recover $152.3 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback